Proteolix Presents Clinical Data From Two Clinical Studies Of Carfilzomib In Multiple Myeloma At The 14th Congress

Proteolix, Inc. announced data from ongoing Phase 2 and Phase 1b clinical trials of carfilzomib for the treatment of multiple myeloma at the 14th Congress of the European Hematology Association (EHA) in Berlin, Germany. Carfilzomib is the first in a new class of selective, irreversible proteasome inhibitors being developed by Proteolix for the treatment of hematologic malignancies and solid tumors.

More: continued here

Filed under: Blood on June 9th, 2009